Navigation Links
Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies

or in combination were administered at different time points. Treatment with the combination regimen reduced the growth of small tumors by 80% to 82% and of well-established tumors by 92% to 94%. The anti-tumor effect of the combination regimen was significantly superior to that of the individual treatments (P < 0.01). Yet the combination therapy was no more toxic to the mice than was docetaxel alone as judged by physical signs and body weight changes.

Tumor microvessel density, which is correlated with tumor growth rates, was further reduced in tumors treated with the combination regimen compared with tumors from single agent-treated animals. In addition, serum PSA levels in combination-treated mice registered a significantly greater decrease (P < 0.05) in one of the tumor models compared to the decrease seen in either the docetaxel-treated or 2aG4-treated animals.

Bavituximab is a targeted monoclonal antibody that binds to a phospholipid called phosphatidylserine, which is located on the inside of normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, thus creating a specific target for anti-cancer treatments. Once bound to the tumor blood vessels, bavituximab alerts the body's immune system to attack the tumor's blood supply, stopping the flow of oxygen and nutrients to the tumor cells and resulting in tumor cell death. As an anti-cancer immunotherapeutic, bavituximab may have broad potential in a wide variety of solid cancers. It is currently in Phase Ia cancer safety trials as a monotherapy and in a Phase Ib trial in combination with docetaxel and other chemotherapy agents in patients with advanced solid cancers, including prostate, breast and lung cancer. Interim data indicate that more than half of the cancer patients in this study who have completed treatment to date were assessed as demonstrating stable disease or an objective response.

Prostate cancer is the most commonly diagnosed c
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
(Date:7/13/2014)... Illinois (PRWEB) July 13, 2014 Hope Palliative ... a monthly grief support group at the Tamarack Senior Living ... be held at 10:30 A.M. on the 3rd Wednesdays of ... 16th, 2014 at the Tamarack Community located at 55 S. ... all bereaved individuals and there is no cost for the ...
(Date:7/13/2014)... 13, 2014 According to The Peripheral ... a comprehensive program that teaches people how to deal ... without medications. This program also provides people with ... peripheral neuropathy , including numbness, prickling, burning, and intense ... that this home treatment program can help people eliminate ...
(Date:7/13/2014)... 2014 Recently, iFitDress.com, one of the ... occasion outfits, has added a new selection of beautiful ... company has launched a promotion for these evening gowns. ... iFitDress.com is now providing thousands of graceful gowns in ... in Britain, America, France, Italy and many other countries. ...
(Date:7/12/2014)... a well-known wedding dress manufacturer and retailer, has added a ... its product line. In addition, the company has launched a ... more benefits for its loyal fans. All its brand ... 72% off. , As a leader in the garment industry, ... a good place for ladies who want to purchase charming ...
(Date:7/12/2014)... 12, 2014 The Chicken Egg ... past five years, buoyed by stable demand for industry ... system. “Eggs are a relatively affordable staple for most ... consumption generally grows in line with the size of ... Furthermore, demand for new specialty egg products with enriched ...
Breaking Medicine News(10 mins):Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3
... have found that a cancer of the lymphatic system, ... produced by a malaria parasite. ,The ... Arnaud Chene and Qijun Chen at the Karolinska Institute ... a large number of children in equatorial Africa causing ...
... India continued to reel under a scorching June sun with ... and Sri Ganganagar in Rajasthan at a searing 46.6 degrees. ... ,Following close behind Sri Ganganagar was Amritsar ... ,"It is summer time and almost all cities in ...
... enough vitamin D, a fact that may put them ... landmark study conducted by Creighton University School of Medicine. ... healthy, postmenopausal women from rural eastern Nebraska.* Participants taking ... nearly three times the U.S. governments Recommended Daily Amount ...
... Human embryonic stem cells (hESC), those very young cells that ... more specialized, contributing to the workings of a wide ... such as Parkinsons is slow to be realized because of ... deriving hESC lines. Additionally, its a politically charged issue in ...
... the chest cavity from the abdominal cavity, is critical ... as congenital diaphragmatic hernia (CDH), results from failure of ... to migrate into the chest cavity. Abnormal lung development, ... fact is the major predictor of morbidity and mortality. ...
... in the last 13 years, but their long-term safety remains ... ,A report in The British Journal of Clinical Pharmacology notes ... meaning consultants have no official guidance on doses to refer ... to estimate a safe and effective dose based on the ...
Cached Medicine News:Health News:Vitamin D Reduces Cancer Risk 2Health News:Dartmouth Professor Makes Case for Ethically Universal Stem Cell Lines 2Health News:Understanding and Treating Congenital Diaphragmatic Hernia 2Health News:Understanding and Treating Congenital Diaphragmatic Hernia 3Health News:Understanding and Treating Congenital Diaphragmatic Hernia 4Health News:UK Researchers Call for Safety Studies of New Anti-epilepsy Drugs for Children 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: